Institutional
JOHNSON & JOHNSON (JNJ)
CIK 0000200406
$652.4M
Reported AUM
16
Positions
Q1 2026
Period
2026-05-13
Filed
The Brief · JOHNSON & JOHNSON (JNJ) · Q1 2026
AI · grounded in 13F
JOHNSON & JOHNSON (JNJ) closed its position in Rallybio Corporation RLYB with a reduction of $2.49M. The fund also exited its holding in Lyell Immunopharma, Inc. LYEL, selling $1.27M. Additionally, the fund trimmed its stake in Nano-X Imaging Ltd. NNOX by 47.4%.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Ticker | Issuer | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc. | $258.1M | 39.57% | — | HELD |
| 2 | NBTX | Nanobiotix S.A. | $173.6M | 26.61% | — | HELD |
| 3 | MGTX | MeiraGTx Holdings plc | $57.5M | 8.82% | — | HELD |
| 4 | RAPP | Rapport Therapeutics, Inc. | $55.8M | 8.56% | — | HELD |
| 5 | CVRX | CVRx, Inc. | $38.1M | 5.84% | — | HELD |
| 6 | CTNM | Contineum Therapeutics Inc. | $25.8M | 3.96% | — | HELD |
| 7 | LEGN | Legend Biotech Corporation | $14.7M | 2.26% | — | HELD |
| 8 | XNCR | Xencor, Inc. | $9.0M | 1.38% | — | HELD |
| 9 | PRCT | Procept BioRobotics Corporation | $9.0M | 1.37% | — | HELD |
| 10 | FATE | Fate Therapeutics, Inc. | $4.1M | 0.62% | — | HELD |
| 11 | NMRA | Neumora Therapeutics, Inc. | $3.6M | 0.55% | — | HELD |
| 12 | RLYB | Rallybio Corporation | $1.4M | 0.21% | +152,901 | NEW |
| 13 | VOR | Vor Biopharma, Inc. | $959K | 0.15% | — | HELD |
| 14 | LAB | Standard BioTools, Inc. | $287K | 0.04% | — | HELD |
| 15 | NNOX | Nano-X Imaging Ltd. | $190K | 0.03% | -75,298 | -47.4% |
| 16 | ACET | Adicet Bio, Inc. | $155K | 0.02% | — | HELD |
| 17 | RLYB | Rallybio Corporation | — | — | -3,636,363 | EXITED |
| 18 | LYEL | Lyell Immunopharma, Inc. | — | — | -41,165 | EXITED |
Source: SEC EDGAR · accession 0000904454-26-000280. 13F discloses long positions only — shorts, foreign equities, and options are excluded.